Humira vs Skyrizi
Adalimumab vs Risankizumab · Comparison Guide
Quick Comparison
| Feature | Humira | Skyrizi |
|---|---|---|
| Generic Name | Adalimumab | Risankizumab |
| Manufacturer | AbbVie | AbbVie |
| Drug Class | TNF-alpha Inhibitor | IL-23 Inhibitor |
| Shared Conditions | Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease | |
Key Differences: Humira vs Skyrizi
Skyrizi requires fewer injections (every 12 weeks vs every 2 weeks) and has shown higher PASI 90/100 clearance rates for psoriasis. Humira covers more conditions including RA, UC, AS, HS, and uveitis. For psoriasis and PsA patients, many dermatologists and rheumatologists now prefer IL-23 inhibitors like Skyrizi over TNF inhibitors as first-line biologics.
💊 Humira (Adalimumab)
- Class: TNF-alpha Inhibitor
- Manufacturer: AbbVie
- Full Humira information →
💊 Skyrizi (Risankizumab)
- Class: IL-23 Inhibitor
- Manufacturer: AbbVie
- Full Skyrizi information →
Skyrizi requires fewer injections (every 12 weeks vs every 2 weeks) and has shown higher PASI 90/100 clearance rates for psoriasis. Humira covers more conditions including RA, UC, AS, HS, and uveitis. For psoriasis and PsA patients, many dermatologists and rheumatologists now prefer IL-23 inhibitors like Skyrizi over TNF inhibitors as first-line biologics.
Neither Humira nor Skyrizi is universally better — the right choice depends on your specific condition, disease severity, insurance formulary, and health history. Your prescriber will determine which is most appropriate based on your clinical situation. BiologicHealthPlus carries both and can help you compare your coverage and costs for either medication.
Switching between biologics is common. Your prescriber will evaluate your current treatment response and determine if a switch is appropriate. BiologicHealthPlus can coordinate the transition including prior authorization for your new medication.
Both Humira and Skyrizi are covered by most commercial insurance plans, Medicare Part D, and Medicaid with prior authorization. BiologicHealthPlus handles insurance verification and prior authorization for both medications at no charge. Most insured patients pay $0–$35/month through manufacturer copay programs.
Humira and Skyrizi both have high cash list prices ($4,000–$9,000/month range) but most commercially insured patients pay $0–$35/month through manufacturer savings programs. BiologicHealthPlus automatically enrolls every patient in all available savings programs at no charge.
✅ BiologicHealthPlus Carries Both Humira and Skyrizi
We handle insurance verification, prior authorization, copay enrollment, and free cold-chain delivery for both medications. Contact us and we'll help you understand your options and costs.
Medical Disclaimer: This comparison is for educational purposes only. The choice between Humira and Skyrizi should be made by your healthcare provider based on your specific medical history, disease severity, and individual circumstances. Last updated: July 2026.